Medford, Massachusetts – July 15, 2021 – Travera, Inc. Has Announced That It Has Recently Closed a $5.5 Million Series a Extension.
“We are very pleased to have attracted outstanding new investors, and continue to enjoy the strong support of our existing investors,” stated Clifford Reid, Ph.D., Travera’s CEO. “With this financing we will continue to accelerate the development and validation of our technology, which will assist physicians to identify effective treatment options for cancer patients.”
The company plans to utilize the funds to continue its ongoing clinical studies to validate the predictive accuracy of its novel biophysical biomarker for matching cancer patients to effective cancer drugs, to launch new clinical studies in other cancer types, including breast cancer and lung cancer, and to achieve CLIA certification for its laboratory testing service.
Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).
The company’s initial test is based on this technology; a new measurement tool called the Suspended Microchannel Resonator (SMR) that makes exquisitely precise measurements of the effects of cancer drugs on cancer cells.
Learn more about Travera